Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
Melanie Janning, Juliane Süptitz, Corinna Albers, et al.
Annals of Oncology (2022) Vol. 33, Iss. 6, pp. 602-615
Open Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)
Jair Bar, Nir Peled, Shiruyeh Schokrpur, et al.
Journal of Thoracic Oncology (2022) Vol. 18, Iss. 2, pp. 169-180
Open Access | Times Cited: 70
Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review
Maxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 7, pp. 973-983
Open Access | Times Cited: 24
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Haiyang Guo, Jun Zhang, Chao Qin, et al.
Cells (2022) Vol. 11, Iss. 20, pp. 3200-3200
Open Access | Times Cited: 48
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
Jingran Ji, Jacqueline V. Aredo, Andrew J. Piper‐Vallillo, et al.
JTO Clinical and Research Reports (2023) Vol. 4, Iss. 3, pp. 100459-100459
Open Access | Times Cited: 30
Targeting HER3 to overcome EGFR TKI resistance in NSCLC
Qiuqiang Chen, Gang Jia, Xilin Zhang, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 10
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 11, pp. 2123-2130
Open Access | Times Cited: 20
Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need
G. Pretelli, Calogera Claudia Spagnolo, Giuliana Ciappina, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8878-8878
Open Access | Times Cited: 20
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
Valentina Favorito, Ilaria Ricciotti, Andrea De Giglio, et al.
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 2, pp. 139-154
Closed Access | Times Cited: 7
Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors
Miriam Grazia Ferrara, Lorenzo Belluomini, Annafrancesca Smimmo, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 184, pp. 103929-103929
Open Access | Times Cited: 16
Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Lanlan Pang, Yihua Huang, Weitao Zhuang, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 12, pp. 2636-2646
Open Access | Times Cited: 5
Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives
Tobias Boch, Jens Köhler, Melanie Janning, et al.
Cancer Biology and Medicine (2022) Vol. 19, Iss. 11, pp. 1543-1564
Open Access | Times Cited: 21
Proteogenomic analysis of air-pollution-associated lung cancer reveals prevention and therapeutic opportunities
Honglei Zhang, Chao Liu, Shuting Wang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment—Comparison with Stage III Disease
Maja Guberina, Christoph Pöttgen, Nika Guberina, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1174-1174
Open Access | Times Cited: 4
Brief Report: The Effectiveness of Osimertinib in Advanced Non-small Cell Lung Cancer Harboring Various EGFR Exon 19 Mutation Variants
Lih-Chyun Chang, Hsiang‐Wei Hu, Min‐Shu Hsieh, et al.
Clinical Lung Cancer (2025)
Open Access
Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need
G. Pretelli, Calogera Claudia Spagnolo, Giuliana Ciappina, et al.
(2023)
Open Access | Times Cited: 10
Mutational characteristics and clinical outcomes for lung adenocarcinoma with EGFR germline mutations
Kelsey Pan, Jennifer Owens, Yasir Y. Elamin, et al.
Journal of Thoracic Oncology (2024)
Closed Access | Times Cited: 3
Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis
Jonathan N. Priantti, Yu Fujiwara, Francisco Cézar Aquino de Moraes, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 3
Distant Cousins From the Same Family—Understanding Uncommon EGFR Mutations
Stephanie P.L. Saw, Molly Li
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 4, pp. 415-418
Closed Access
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
Adam Barsouk, Omar Elghawy, Alan G. Watts, et al.
Lung Cancer (2025) Vol. 203, pp. 108551-108551
Open Access
Potential biomarkers of primary resistance to first- and second-generation EGFR-TKIs in non-small-cell lung cancer: a real-world study
Jingyi Wang, B. Chen, Xingxiang Pu, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Imaging bridges pathology and radiology
Martin‐Leo Hansmann, Frederick Klauschen, Wojciech Samek, et al.
Journal of Pathology Informatics (2023) Vol. 14, pp. 100298-100298
Open Access | Times Cited: 9
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)
Elio Gregory Pizzutilo, Alberto Giuseppe Agostara, Sara Oresti, et al.
ESMO Open (2024) Vol. 9, Iss. 6, pp. 103592-103592
Open Access | Times Cited: 3
Proteogenomic analysis of air-pollution-associated lung cancer reveals prevention and therapeutic opportunities
Honglei Zhang, Chao Liu, Shuting Wang, et al.
(2024)
Open Access | Times Cited: 3
Saturation profiling of drug-resistant genetic variants using prime editing
Younggwang Kim, Hyeong-Cheol Oh, Seung‐Ho Lee, et al.
Nature Biotechnology (2024)
Closed Access | Times Cited: 3
Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study)
Hong‐Shuai Li, Shouzheng Wang, Haiyan Xu, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5307-5307
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top